AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Estradiol 17-beta-dehydrogenase 11

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8NBQ5

UPID:

DHB11_HUMAN

Alternative names:

17-beta-hydroxysteroid dehydrogenase 11; 17-beta-hydroxysteroid dehydrogenase XI; Cutaneous T-cell lymphoma-associated antigen HD-CL-03; Dehydrogenase/reductase SDR family member 8; Retinal short-chain dehydrogenase/reductase 2; Short chain dehydrogenase/reductase family 16C member 2

Alternative UPACC:

Q8NBQ5; Q96HF6; Q9UKU4

Background:

Estradiol 17-beta-dehydrogenase 11, also known as 17-beta-hydroxysteroid dehydrogenase 11, plays a crucial role in androgen metabolism during steroidogenesis. It converts androstan-3-alpha,17-beta-diol to androsterone, impacting steroid synthesis through metabolizing compounds or generating inhibitory metabolites. Despite its limited activity towards DHEA, A-dione, and testosterone, it is identified as a tumor-associated antigen in cutaneous T-cell lymphoma.

Therapeutic significance:

Understanding the role of Estradiol 17-beta-dehydrogenase 11 could open doors to potential therapeutic strategies, especially in the context of its involvement in androgen metabolism and its association with cutaneous T-cell lymphoma.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.